Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lentinula edodes, commonly known as shiitake mushroom, has been studied for its potential neuroprotective effects, including possible applications in Alzheimer’s Disease (AD). The primary scientific rationale is based on the presence of bioactive compounds in L. edodes mycelia, such as polysaccharides (notably lentinan), ergothioneine, and various antioxidants, which may help reduce oxidative stress and inflammation—two key factors implicated in AD pathology.

Preclinical studies have shown that extracts from L. edodes mycelia can exert neuroprotective effects in cell culture and animal models by reducing amyloid-beta toxicity, inhibiting acetylcholinesterase activity, and modulating inflammatory pathways. For instance, some studies in mice have reported improvements in memory deficits and reduced markers of neuroinflammation after administration of shiitake mycelial extracts. Additionally, ergothioneine, a potent antioxidant abundant in shiitake, has been inversely correlated with cognitive decline in some observational studies.

However, clinical evidence in humans is currently limited. Although L. edodes and its extracts have a long history of use in traditional Asian medicine for general health and longevity, their specific application to Alzheimer’s Disease is primarily driven by emerging biomedical research rather than established traditional use. Given the promising but preliminary nature of the data, the evidence level is rated as 2/5. More robust, controlled clinical trials are needed to determine the efficacy and safety of L. edodes mycelia in humans with AD.

More about lentinula edodes mycelia
More about Alzheimer's Disease

Other ingredients used for Alzheimer's Disease

Other health conditions supported by lentinula edodes mycelia

Products containing lentinula edodes mycelia